Phase 4 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are neurologically normal — meaning free from unstable neurological or psychiatric conditions, as confirmed by a neurological examination at the start of the trial
• People who agree to have unenhanced brain MRI scans (MRI scans without contrast dye) at the start of the trial and again after 5 years
• People who have at least one of the following health situations: medium to high risk for breast cancer or dense breast tissue requiring MRI screening; elevated PSA levels under active monitoring for prostate cancer; chronic liver disease (such as mild liver cirrhosis, post-hepatitis liver conditions, or primary sclerosing cholangitis) being monitored for liver cancer; low-grade colorectal cancer or a type of slow-growing tumour being monitored for spread to the liver; or a specific type of small pancreatic cyst (branch-duct IPMN, no larger than 2 cm) under imaging surveillance

For people joining the contrast dye (GBCA) groups only:

• People who are likely to have 5 or more MRI scans using the same contrast dye at least once a year over the 5-year study period
• People who have had up to 3 previous MRI scans using contrast dye before the trial starts may still be eligible, provided the same contrast dye was used and is clearly documented (confirm with trial site)

For people joining the control group (no contrast dye):

• People who have never received contrast dye in an MRI scan and are unlikely to receive any during the study
• People willing to have unenhanced brain MRI scans at the start and at year 5, and to continue with their usual clinically recommended scans (MRI without dye, CT, ultrasound, or X-ray) in years 1 through 4

Who may not be able to join:

• People with a current or past history of certain neurological or psychiatric conditions — including stroke-related brain disease, multiple sclerosis, neurodegenerative disease, epilepsy, prior brain surgery, psychotic disorders, schizophrenia, active or recent major depression or bipolar disorder, uncontrolled severe migraines, uncontrolled or recently treated anxiety or depression (within 6 months of enrolment), certain developmental conditions, or those whose screening test scores fall below a set cognitive threshold (confirm with trial site)
• People who are currently receiving, have previously received, or are planning to receive chemotherapy or radiation to the brain
• People taking medications that affect thinking, memory, or movement
• People with substance or alcohol misuse, as assessed by the trial investigator
• People whose liver disease is caused by alcohol (alcoholic cirrhosis)
• People with reduced kidney function, defined by a specific blood test result falling below a set level (confirm with trial site)
• People with a history of significant exposure to certain harmful chemicals through their environment or work, including heavy metals (such as lead, mercury, or manganese), pesticides, solvents, or carbon monoxide
• People whose medical condition requires more than one contrast-enhanced MRI scan every 6 months
• People who are pregnant or breastfeeding
• People who have metal joint implants or prostheses in their body

For people in the contrast dye (GBCA) groups only:

• People who have previously received a different contrast dye — or a generic version of a contrast dye — other than the specific one to be used in this trial

For people in the control group only:

• People who have ever had a contrast dye injection for an MRI scan
• People who have any reason they cannot safely have an unenhanced MRI scan

Important: Always verify eligibility with the trial site directly before applying.